Genomics driven-oncology: challenges and perspectives.

摘要: Molecularly defined subgroups of tumors characterized by specific driver mutations have been identified in the majority cancers. The availability novel drugs capable targeting signaling pathways activated genetic derangements has led to hypothesize possibility treat patients based on their genomic profile. A clear example is represented lung adenocarcinoma for which it possible identify alterations approximately 75% cases. Among these, RET fusion transcripts are detectable about 1–2% adenocarcinomas and might represent targets therapeutic intervention with kinase inhibitors. However, a number issues need be addressed make genomics-driven oncology routinely accessible cancer patients, including: 1) methods molecular diagnostics that allow comprehensive characterization starting from low input DNA/RNA; 2) identification reliable reproducible biomarkers response/resistance targeted agents; 3) assessment role tumor heterogeneity response pathways.